A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma - Regional Cancer Care Associates LLC

Clinical Trials

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Type of Cancer
Genito-Urinary
Locations
Hackensack
Sponsor
Aveo
Protocol Number
AV-951-15-303
Cancer Diagnosis
To Learn More Call
201-510-0910